Principal Financial Group Inc. Reduces Stake in Cellectis S.A. (NASDAQ:CLLS)

Principal Financial Group Inc. lowered its position in Cellectis S.A. (NASDAQ:CLLS) by 5.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 411,800 shares of the biotechnology company’s stock after selling 25,200 shares during the period. Principal Financial Group Inc. owned about 0.74% of Cellectis worth $881,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in Cellectis in the second quarter worth about $29,000. First Affirmative Financial Network purchased a new position in shares of Cellectis in the third quarter worth approximately $45,000. Finally, Long Focus Capital Management LLC grew its position in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares during the period. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Stock Performance

CLLS opened at $1.68 on Friday. The company has a 50 day simple moving average of $1.84 and a two-hundred day simple moving average of $2.01. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The firm has a market cap of $93.10 million, a P/E ratio of -1.29 and a beta of 3.08. Cellectis S.A. has a 1-year low of $1.41 and a 1-year high of $3.38.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The firm had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. During the same period in the prior year, the company posted ($0.31) EPS. Equities analysts forecast that Cellectis S.A. will post -0.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CLLS shares. Barclays dropped their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. StockNews.com initiated coverage on Cellectis in a research report on Tuesday, December 31st. They set a “sell” rating on the stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.